van der Schans S - Search Results

1

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands.

Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Velikanova R, et al. Among authors: van der schans s. Value Health. 2022 Oct;25(10):1696-1704. doi: 10.1016/j.jval.2022.06.010. Epub 2022 Aug 11. Value Health. 2022. PMID: 35963838 Free article.

2

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.

van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, Rutten-van Mölken MPMH. van der Schans S, et al. Pharmacoeconomics. 2017 Jan;35(1):43-63. doi: 10.1007/s40273-016-0448-2. Pharmacoeconomics. 2017. PMID: 27592021 Free PMC article. Review.

3

The impact of patent expiry on drug prices: insights from the Dutch market.

van der Schans S, Vondeling GT, Cao Q, van der Pol S, Visser S, Postma MJ, Rozenbaum MH. van der Schans S, et al. J Mark Access Health Policy. 2020 Dec 1;9(1):1849984. doi: 10.1080/20016689.2020.1849984. J Mark Access Health Policy. 2020. PMID: 33312457 Free PMC article.

4

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands.

Hagendijk ME, van der Schans S, Boersma C, Postma MJ, van der Pol S. Hagendijk ME, et al. Among authors: van der schans s. Eur J Health Econ. 2021 Aug;22(6):991-999. doi: 10.1007/s10198-021-01303-2. Epub 2021 Apr 7. Eur J Health Econ. 2021. PMID: 33829344 Free PMC article.

5

A novel perspective on pharmaceutical R&D costs: opportunities for reductions.

van der Schans S, De Loos F, Boersma C, Postma MJ, Büller H. van der Schans S, et al. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):167-175. doi: 10.1080/14737167.2022.1987219. Epub 2021 Oct 21. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 34595997

6

Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling-The Tool of Choice for Assessing Public Finance Sustainability.

van der Schans S, Schöttler MH, van der Schans J, Connolly MP, Postma MJ, Boersma C. van der Schans S, et al. Vaccines (Basel). 2023 Apr 10;11(4):823. doi: 10.3390/vaccines11040823. Vaccines (Basel). 2023. PMID: 37112735 Free PMC article.

7

Monitoring physical impact and recovery of pancreatic cancer treatment using consumer wearable health data: A case report.

van der Schans CP, van der Schans S, van der Schans J, Mylius C, Klaase J. van der Schans CP, et al. Among authors: van der schans s. Digit Health. 2023 May 22;9:20552076231177127. doi: 10.1177/20552076231177127. eCollection 2023 Jan-Dec. Digit Health. 2023. PMID: 37252255 Free PMC article.

8

Myodesis or myoplasty in trans-femoral amputations. What is the best option? An explorative study.

Geertzen JHB, van der Schans SM, Jutte PC, Kraeima J, Otten E, Dekker R. Geertzen JHB, et al. Among authors: van der schans sm. Med Hypotheses. 2019 Mar;124:7-12. doi: 10.1016/j.mehy.2019.01.008. Epub 2019 Jan 16. Med Hypotheses. 2019. PMID: 30798921 No abstract available.

9

Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry.

Strobbe L, van der Schans SA, Heijker S, Meijer JW, Mattijssen EJ, Mandigers CM, de Kievit IM, Raemaekers JM, Hebeda KM, van Krieken JH. Strobbe L, et al. Among authors: van der schans sa. Leuk Lymphoma. 2014 May;55(5):1018-22. doi: 10.3109/10428194.2013.827787. Epub 2013 Sep 10. Leuk Lymphoma. 2014. PMID: 23885798

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page